Abstract
BACKGROUND: Blood product administration plays a major role in the management of patients treated with extracorporeal membrane oxygenation (ECMO) and may be a contributor to morbidity and mortality. METHODS: We performed a systematic review of the published literature to determine the current usage of packed red cell transfusions. Predefined search criteria were used to identify journal articles reporting transfusion practice in ECMO by interrogating EMBASE and Medline databases and following the PRISMA statement. RESULTS: Out of 1579 abstracts screened, articles reporting ECMO usage in a minimum of 10 adult patients were included. Full texts of 331 articles were obtained, and 54 were included in the final analysis. All studies were observational (2 were designed prospectively, and two were multicentre). A total of 3808 patients were reported (range 10-517). Mean exposure to ECMO was 8.2 days (95% confidence interval (CI) 7.0-9.4). A median of 5.6% was not transfused (interquartile range (IQR) 0-11.3%, 19 studies). The mean red cell transfusion per ECMO run was 17.7 units (CI 14.2-21.2, from 52 studies) or 2.60 units per day (CI 1.93-3.27, from 49 studies). The median survival to discharge was 50.8% (IQR 40.0-64.9%). CONCLUSION: Current evidence on transfusion practice in ECMO is mainly drawn from single-centre observational trials and varies widely. The need for transfusions is highly variable. Confounding factors influencing transfusion practice need to be identified in prospective multicentre studies to mitigate potential harmful effects and generate hypotheses for interventional trials.